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Abstract: Since tumor-draining pulmonary vein blood (PV) is enriched in tumor-secreted products,
we hypothesized that it would also be enriched in tumor-derived exosomes, which would be
important in the metastasis process. We characterized exosomes from PV of 61 resected non-small
cell lung cancer (NSCLC) patients to evaluate its potential as relapse biomarkers. Exosomes were
characterized using transmission electron microscopy, western blot and nanoparticle tracking analysis
and we examined time to relapse (TTR) and overall survival (OS). Differences between PV and
peripheral vein were found. PV was enriched in smaller exosomes than the paired peripheral vein
(p = 0.01). Moreover, PV exosome size mode was able to identify relapsed patients (Area under
the curve [AUC] = 0.781; 95%CI: 0.6641–0.8978), in whom exosome size was smaller (<112 nm;
p < 0.001). The combination of PV exosome size and N (lymph node involvement) showed an AUC
of 0.89 (95%CI: 0.80–0.97). Moreover, smaller PV exosome size was associated with shorter TTR
(28.3 months vs. not reached, p < 0.001) and OS (43.9 months vs. not reached, p = 0.009). Multivariate
analyses identified PV exosome size and stage as independent prognostic markers for TTR and OS.
PV exosome size is a promising relapse biomarker after surgery that can add valuable information to
clinical variables.
Keywords: exosome; extracellular vesicles; tumor-draining vein; relapse; lung cancer; NSCLC
1. Introduction
Treatment of non-small cell lung cancer (NSCLC) depends on disease stage. In early and locally
advanced stages, surgical resection of the tumor is, when possible, the first option and is considered
curative [1]. In stage II and IIIa, adjuvant chemotherapy after surgery has been shown to improve
survival [2]. However, the prognosis of these patients is still dismal—five-year survival rates of
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60–80% for stage I, 20–50% for stage II and 23% for stage IIIA patients—due to high relapse rates
(40%) after surgery. One of the factors associated with patient relapse is the presence of circulating
tumor cells (CTCs) in peripheral blood, which has been associated with worse prognosis [3]. However,
studies in peripheral blood are limited by the low number of CTCs that can be detected, leading
some investigators to analyze the utility of detecting CTCs and other biomarkers in blood from the
tumor-draining pulmonary vein, which can better identify patients with a high risk of relapse after
surgery [4]. While these results are interesting, the metastatic process cannot be explained only by the
presence of CTCs, since their survival in the bloodstream, the extravasation process and the anchorage
to the metastatic site are challenging. Recently, it has been shown that extracellular vesicles signals
emitted by the primary tumor that are picked up by specific cells with the appropriate receptors [5],
can contribute to the oncogenesis and metastasis process. The target cells can be located either in the
local microenvironment of the tumor or in distant organs, since exosomes can reach the bloodstream.
Extracellular vesicles are involved in several biological functions, including cross-talk between cells,
tumorogenesis, drug resistance, angiogenesis promotion, and metastasis [6,7]. The extracellular
vesicles are classified according to size and biogenesis as exosomes (<150 nm and produced from
multivesicular bodies) or microvesicles (>150 nm and formed through the direct budding of the plasma
membrane) [7]. Exosomes have been shown to play a role in the metastatic process through the
creation of a pre-metastatic niche that facilitates the anchorage and growth of CTCs in the metastatic
site [8]. Recently, it has been also shown in vitro and in vivo in liver cancer that primary-tumor
derived exosomes can deliver their cargo on CTCs and enhance their adhesion supporting metastasis
formation [9].
To our knowledge, most of the studies have been focused on the study of exosome cargo to identify
diagnosis/prognosis biomarkers, such as exosomal microRNAs [10] or exosomal proteins [11], and few
studies have analyzed whether exosome levels themselves could be used as a disease parameter.
Recently, König et al. have shown that the analysis of extracellular vesicles concentration in blood
of breast cancer patients may serve as a complementary parameter reflecting the status of minimal
residual disease as well as therapy and disease outcome in parallel with CTC investigation [12].
We hypothesized that the quantification and size distribution of exosomes in circulation could be
an indicator of tumor metastatic capacity in non-small cell lung cancer. However, we speculate that
tumor-derived exosomes in peripheral blood will be very diluted in comparison with tumor-draining
pulmonary vein as previously observed with CTCs, especially in early-stage patients [13–15]. Therefore,
we hypothesized that the analysis of tumor-derived exosomes could provide more reliable results
in blood obtained from the pulmonary vein, where the products released by the tumor would be
concentrated. We have compared the quantity and size of exosomes from tumor-draining pulmonary
and paired peripheral vein and evaluated their potential as a biomarker of relapse in NSCLC.
2. Results
2.1. Patients
The analysis included 61 patients (Table 1). Twenty-three patients (37.7%) received adjuvant
cisplatin-based chemotherapy (2 stage IB, 16 stage II, and 5 stage III). None of the patients received
neoadjuvant treatment. Median follow-up time was 40.87 months (IQR: 23.53–49.27). Twenty-one
patients (34.4%) relapsed after surgery, 15 with distant metastases. Seventeen patients (27.8%) died
during follow-up; although the cause of death was not recorded, 14 (82.4%) of them died after relapse
while three (17.6%) died without relapse, suggesting that lung cancer was the main cause of death
(p < 0.001). Pulmonary vein blood was obtained from the entire cohort, but blood from the peripheral
vein was only obtained from 55 of the 61 patients (92%).
Cancers 2019, 11, 249 3 of 11
Table 1. Main clinical characteristics of the patients and univariate p-values (log-rank test) for time to
relapse (TTR) and overall survival (OS).
Characteristics Value
N = 61 TTR OS
N (%) p-Value p-Value
Sex Male 41 (67.2)
Female 20 (32.8) 0.5427 0.6291
Age, y Mean (Range) 63 (32–80)
≤65 34 (55.7)
>65 27 (44.3) 0.8 0.2253
ECOG PS 0 26 (42.6)
1 35 (57.4) 0.4723 0.3479
Pathological Stage I 30 (49.2)
II 24 (39.3)
III 7 (11.5) 0.0069 0.0082
Histology Adenocarcinoma 35 (57.4)
Squamous cell
carcinoma 16 (26.2)
Others 10 (16.4) 0.7562 0.9579
Type of surgery Segmentectomy 5 (8.2)
Lobectomy/bilobectomy 48 (78.7)
Pneumonectomy 7 (11.5)
Atypical Resection 1 (1.6) 0.3963 0.4178
Smoking history Current Smoker 32 (52.5)
Former Smoker 24 (39.3)
Never smoker 5 (8.2) 0.1118 0.1881
FEV1 Liters (±SD) 2.4 (±0.6)
%pred (±SD) 76.8 (±16.1) - -
FVC Liters (±SD) 3.56 (±0.74)
%pred (±SD) 88 (±16.42) - -
FEV1/FVC Ratio (±SD) 67.2 (±9.74) - -
Tumor size mm (±SD) 38.3 (±23.2) - -
Received adjuvant chemotherapy Yes 23 (37.7)
No 38 (62.3) 0.0113 0.1958
Experienced recurrence No 40 (65.6)
Yes 21 (34.4) - -
ECOG PS, Eastern Cooperative Oncology Group performance status; FEV1, forced expiratory volume in 1 s; FVC,
forced vital capacity. Bold for p < 0.05.
2.2. Exosome Characterization
Transmission electron microscopy (TEM) morphological analysis showed the presence of round
27–200 nm vesicles. To further validate that these vesicles were, at least in part, exosomes, the presence
of the established exosomal markers TSG101 and CD63 was determined using western blot, which
confirmed the presence of the exosomes (Figure 1A). Using nanoparticle tracking analysis (NTA),
which uses the properties of both Brownian motion and light scattering to obtain the particle size
distribution of samples in a liquid suspension (Video S1), we obtained a size distribution profile graph
(Figure 1B), and concentration (nanoparticles/mL) and size measures for each sample. The median
concentration in all samples by NTA was 3.815 × 109 particles per mL (range: 7.72 × 108–2.64 × 1010)
and the mode of particle diameter was 114.5 nm (range: 85.1–173.3).
2.3. Exosome Concentration and Clinical Characteristics
When we compared the overall exosome concentration between the pulmonary and peripheral
veins, no significant differences were observed (p = 0.1214, Figure 1C). However, the sub-analysis
of the specific levels of different exosome sizes showed that the pulmonary vein was enriched in
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exosomes of 30–50 nm (p = 0.0496) while no significant differences were observed for other group sizes
(51–150/151–1000 nm, Figure 1D).
The correlation of the overall exosome concentration with the main clinical characteristics of the
patients showed that the quantity of exosomes in the pulmonary vein was related to the T stage (of
the TNM classification), where T1 patients had significantly fewer exosomes than others (p = 0.0204,
Figure 1E). However, this association was not observed in the paired blood from the peripheral
vein (p = 0.6251, Figure 1F). Moreover, when we grouped patients according to median tumor size,
those with tumors smaller than 35 mm had fewer pulmonary vein exosomes than those with larger
tumors (p = 0.01). No significant association was observed in the peripheral vein.
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Figure 1. (A) Exosomes were characterized by transmission electron microscopy using negative 
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Figure 1. (A) Exosomes were characterized by transmission electron microscopy using negative staining
and Western blot using the exosome marker TSG101. (B) The quantification and size analysis were
performed by Nanosight. An example of the size distribution graph obtained is shown. (C) Boxplot
showing exosome levels in pulmonary and peripheral vein in non-sm ll cell lung cancer (NSCLC)
patients. (D) Bar plot showing exosomal size levels in pulmonary and peripheral vein according to
three size groups: 30–50 nm, 51–150 nm and 151–1000 nm. (E) Boxplot showing pulmonary vein
exosome levels according to T stage in NSCLC patients. (F) Boxplot showing peripheral vein exosome
levels according to T stage in NSCLC patients.
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2.4. Pulmonary Vein Exosome Size Identifies Patients Who Relapse after Curative Surgery
Significant differences in exosome size between pulmonary and peripheral veins were observed
(Figure 2A). Pulmonary vein exosomes were significantly smaller than those from the paired peripheral
vein (mean mode size 111.8754 vs. 118.1545; p = 0.0134).
The size of exosomes from the pulmonary vein was significantly smaller in relapsed patients
than in non-relapsed patients (mean size 105.26 vs. 115.35 nm, p < 0.001) (Figure 2B). Nevertheless,
these differences in size were not observed in the peripheral vein (p = 0.62, Figure 2C).
ROC curves were generated to investigate exosome size as a predictive biomarker of relapse
after surgery. The area under the curve (AUC) value according to pulmonary vein exosome size
was 0.78 (95% confidence interval (CI), 0.6641–0.8978) with a sensitivity of 67.5% and specificity of
81% in distinguishing patients who relapse after surgery in its best threshold (112 nm) (Figure 2D).
Using 112 nm as a threshold, the negative predictive value was 87.1%, and the positive predictive
value was 56.7%.
In order to compare the impact of the pulmonary vein exosome size with other clinical factors,
lymph node involvement (N), and disease stage were included in the analysis. N showed an AUC of
0.76 (95% CI: 0.64–0.88), and disease stage showed an AUC of 0.71 (95% CI, 0.59–0.84). To verify that
no other confounding parameters could have affected these results, we performed a binary logistic
regression multivariate analysis for relapse to verify the independent impact of pulmonary vein
exosome size to predict relapse after curative surgery. Pulmonary vein exosome size (hazard ratio
(HR), 0.87 (95%CI, 0.79–0.94); p = 0.0019) and N (HR, 7.1 (95% CI, 2.48–27.14); p = 0.0011) emerged as
independent markers of relapse. Interestingly, when we combined pulmonary vein exosome size and
N, a good AUC of 0.89 (95% CI, 0.80–0.97) was obtained.
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Figure 2. The relationship between exosomal size and relapse after surgery in NSCLC patients.
(A) Boxplot showing exosome size distribution (size mode) in pulmonary and peripheral vein in
NSCLC patients. (B) Boxplot showing pulmonary vein exosomal size in relapsed and non-relapsed
NSCLC patients. (C) Boxplot showing peripheral vein exosomal size in relapsed and non-relapsed
NSCLC patients. (D) ROC curve analysis of pulmonary vein exosomal size values predicting relapse
after surgery in NSCLC patients. The cut-off for disease relapse after surgery was set at 112 nm.
The area under the curve of 0.78 with pulmonary vein exosomal size values of <112 nm resulted in a
sensitivity of 81% and specificity of 67.5%.
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2.5. Pulmonary Vein Exosome Size Is Associated with Outcome after Curative Surgery
The smaller exosome size (<112 nm) in the pulmonary vein was associated with shorter TTR
(28.3 months vs. not reached; p = 0.0004; Figure 3A) and shorter OS (43.9 months vs. not reached;
p = 0.0092; Figure 3B). No significant differences were observed when exosome size was analyzed in
the peripheral vein (Figure 3C,D).
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Figure 3. Kaplan-Meier survival analysis of associations between exosomal size and time to relapse
(TTR) and overall survival (OS) among patients with NSCLC. (A) TTR according to pulmonary vein
exosomal size. (B) OS according to pulmonary vein exosomal size. (C) TTR according to peripheral
vein exosomal size. (D) OS according to peripheral vein exosomal size.
An exploratory analysis of patients with stage I disease (n = 30) showed that exosome size
discrimin ted stage I pa ients with a high relapse risk (AUC=0.76 (95% CI, 0.53–0.98)) (Figure 4A).
In addition, a trend towards shorter TTR (p = 0.0763) and OS (p = 0.1190) was observed for patients
with smaller exosome size (Figure 4B,C).Cancers 2019, 11, x  7 of 11 
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Figure 4. (A) ROC curve analys s of pulmonary vein exo omal size values predicting relapse after
surgery in stage I NSCLC patients. The cut-off for relapse was set at 112.3 nm. The area under the
curve of 0.76 with pulmonary vein exosomal size values of <112.3 nm resulted in a sensitivity of 80%
and specificity of 72%. (B) Kaplan-Meier survival analysis of associations between pulmonary vein
exosomal size and time to relapse (TTR) among patients with stage I NSCLC. (C) Kaplan-Meier survival
analysis of the association between pulmonary vein exosomal size and overall survival (OS) among
patients with stage I NSCLC.
2.6. Cox Modeling of Relapse and Survival
In the multivariate Cox analyses, exosome size emerged as an independent risk factor for TTR
(HR, 6.66 (95%CI, 2.06–21.51); p = 0.0015) and OS (HR, 4.55 (95%CI, 1.43–14.49); p = 0.0104). Stage was
also an independent marker of TTR (HR, 2.42 (95% CI, 1.16–5.03); p = 0.0180) and OS (HR, 2.93 (95% CI,
1.46–5.84); p = 0.0024) (Table 2).
Table 2. Cox multivariate analyses of time to relapse and overall survival. Bold for p < 0.05.
Time to Relapse Hazard Ratio (HR, 5% CI) p-Value
Stage 2.42 (1.16–5.03) 0.0180
Adjuvant chemotherapy 1.59 (0.59–4.26) 0.3563
Exosome size in pulmonary vein <112 nm 6.66 (2.06–21.51) 0.0015
Overall Survival HR (95% CI) p-value
Stage 2.93 (1.46–5.84) 0.0024
Exosome size in pulmonary vein <112 nm 4.55 (1.43–14.49) 0.0104
3. Discussion
In the present study, we have examined exosome size distribution and levels to evaluate their
potential to predict relapse of resected NSCLC patients. Importantly, exosomes were analyzed in blood
obtained from the pulmonary vein during surgery and compared with those obtained from peripheral
blood before tumor resection. Previous studies showed that blood obtained from a tumor-draining
vein is enriched in tumor-secreted products, including CTCs [13], which led us to hypothesize that
it would be enriched in primary tumor-derived exosomes. Our results showed that pulmonary vein
blood was enriched in exosomes of 30–50 nm, while no differences were observed in other size
ranges. Remarkably, pulmonary vein overall exosome levels were more highly correlated with tumor
characteristics than those in peripheral blood. In this line, we observed a significant association
between T stage and pulmonary vein—but not peripheral vein—exosome levels. T stage is related to
tumor size and we observed higher pulmonary vein exosome levels in tumors larger than the median
(35 mm). Pulmonary vein exosome analysis may more closely represent tumor characteristics than the
analysis of peripheral vein.
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Moreover, significant differences in exosome size distribution (mode of size) were observed
between the pulmonary and peripheral veins, where pulmonary vein exosomes were smaller than
peripheral vein exosomes. Interestingly, the size of pulmonary vein exosomes correlated with the
risk of post-surgical relapse and survival. Patients with smaller pulmonary vein exosomes had a
higher risk of relapse and shorter TTR and OS, while no differences were observed according to
peripheral vein exosome size. In line with our results, an in vitro study in prostate cancer found that
the amount and size of exosomes changed after the acquisition of resistance to docetaxel treatment,
where the size of exosomes secreted by resistant cells was smaller than of those secreted by the sensitive
cells [5]. Recently, Kim et al. reported that extracellular vesicle size was an independent predictor of
progression-free survival at first response assessment to chemotherapy in pancreatic cancer [16]. Taken
together with our results, these findings allow us to speculate that a more aggressive cell phenotype is
linked to the production of smaller exosomes.
The evaluation of pulmonary vein exosome size was able to identify patients who relapsed with
an accuracy of 72%. The AUC of 0.78 for exosome size observed in our cohort is fair and was able
to discriminate relapsed patients more accurately than disease stage (AUC of 0.71), or N (AUC of
0.76). Interestingly, the good AUC of 0.89 for the combination of exosome size and N suggest that
exosome size may potentially complement clinical variables in identifying patients with a high risk
of relapse, who could benefit from more aggressive treatment. This is especially relevant for stage I
patients, who do not receive any post-surgical treatment, in comparison with stage II–IIIa patients
who benefit from platinum-based chemotherapy [1]. In a sub-analysis of stage I patients, exosome
size as a continuous variable also discriminated patients with a high relapse risk and shorter TTR
(Cox univariate HR, 0.91 (95% CI, 0.829–0.9998); p = 0.0496). These preliminary results, if confirmed
in larger studies, indicate that pulmonary vein exosome size is a promising biomarker of relapse for
stage I patients.
Despite the benefits described in our work and others [13–15] of the analysis of tumor-secreted
products in tumor-draining pulmonary vein, the obtaining of this type of sample could be considered
invasive in comparison with peripheral blood analysis. However, we have to take into account that
this analysis is limited to surgical NSCLC patients, where the access to the pulmonary vein is neither
modifying the routine surgical procedure nor requiring additional lung dissection. The tumor-draining
pulmonary vein is punctured immediately on opening the chest prior to beginning the resection of the
tumor. This approach was safe with no complications reported in our cohort of patients or in previous
studies [13]. Moreover, most of the resected NSCLC patients are early-stage (I–II) patients in which the
number of tumor-secreted products in peripheral blood is more limited, and, therefore, they will be
the most benefited from the tumor-draining pulmonary vein analysis.
Several authors have found that exosomes and their cargo, analyzed in peripheral blood [11,17,18]
and bronchoalveolar lavage [19], can be useful diagnostic biomarkers in NSCLC. However, to our
knowledge, this is the first report to analyze exosomes in blood from the pulmonary vein and to show
that they can be used as an independent prognostic biomarker for relapse and survival after surgery
in NSCLC. Further investigation in a larger cohort of patients is warranted to validate these findings
and explore the potential for exosome size analysis to be used in the clinical management of resected
NSCLC patients.
4. Material and Methods
4.1. Patient Samples
The study included 61 stage I-IIIa NSCLC patients who underwent complete surgical resection in
our institution (Table 1). Blood (4 mL in EDTA tube) from the tumor-draining pulmonary vein was
obtained during the surgery before tumor resection or vessel ligation. Blood from a peripheral vein was
obtained by the nurse anesthesiologist before the start of surgery. Plasma obtained by centrifugation
was stored at −80 ◦C until processing. Written informed consent was obtained from each participant
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in accordance with the Declaration of Helsinki and the study was approved by the Clinical Research
Ethics Committee of the Hospital Clínic de Barcelona (project approval number HCB/2017/1052).
4.2. Exosome Purification and Characterization
Exosomes were isolated from 200 µL of plasma by ultracentrifugation in a Sorvall MX Plus
Micro-Ultracentrifuge with S140AT Rotor as previously described [20]. Pelleted exosomes resuspended
in 200 µL of dPBS: 100 µL were used for exosome characterization by TEM and Western blot and
100 µL were used for exosome quantification and size analysis by NTA. Exosomal marker TSG101
was analyzed by Western blot as previously described [20,21], and CD63 was analyzed using Rabbit
polyclonal to CD63 (ab68418, from Abcam, Cambridge, UK). For TEM analysis, exosomes in dPBS
were fixed in a final concentration of 2% paraformaldehyde, mounted on copper-mesh formvar grids
and negatively stained by 2% uranyl acetate. Samples were observed using a TEM JEOL J1010 80 kV at
the Electron Cryomicroscopy Unit of the University of Barcelona (CCiTUB, Barcelona, Spain). NTA
analysis was performed on a Nanosight NS300 in the ICTS “NANBIOSIS” (Biomaterial Processing and
Nanostructuring Unit of the CIBER in Bioengineering, Biomaterials & Nanomedicine at Institut de
Ciència de Materials de Barcelona, CSIC, Campus UAB, Bellaterra, Barcelona, Spain).
4.3. Statistical Analysis
Assumptions of distributional normality were tested using the Shapiro-Wilk test and quantile-
quantile plot. Continuous data were tested with the T-test (two groups) or ANOVA (more than two
groups) when normally distributed and the Mann–Whitney U test or Kruskal Wallis test when not
normally distributed. Receiver operating characteristic (ROC) curves were calculated using R package
pROC. Time to relapse (TTR) was calculated as the time between resection and recurrence or last
follow-up and overall survival (OS) as the time between resection and death from any cause or last
follow-up. Kaplan-Meier curves for TTR and OS were drawn and compared by means of a log-rank
test. All clinical factors with p < 0.1 in the univariate analysis were included in the Cox multivariate
regression analyses. Statistical significance was set at p ≤ 0 .05. All statistical analyses were performed
using R v3.3 (R Foundation for Statistical Computing, https://www.r-project.org/).
5. Conclusions
The evaluation of tumor-draining pulmonary vein exosome size is a promising prognostic
biomarker for relapse and survival after surgery and can add valuable information to clinical variables.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6694/11/2/249/s1,
Video S1. Video captured during the nanoparticle tracking analysis (NTA) measurement in Nanosight NS300
equipment showing the movement of particles (exosomes) in suspension.
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